<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682107</url>
  </required_header>
  <id_info>
    <org_study_id>16-0119</org_study_id>
    <secondary_id>HHSN272201300016I</secondary_id>
    <nct_id>NCT03682107</nct_id>
  </id_info>
  <brief_title>Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device</brief_title>
  <official_title>A Phase I, Randomized, Placebo Controlled, Double-Blind, Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection System in Normal Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48&#xD;
      males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet&#xD;
      all eligibility criteria. This trial is designed to assess the safety, reactogenicity and&#xD;
      immunogenicity of an Andes Virus (ANDV) DNA vaccine for the prevention of Hantavirus&#xD;
      Pulmonary Syndrome (HPS). ANDV DNA vaccine or placebo will be administered using the&#xD;
      PharmaJet Stratis(R) Needle-Free Injection System. The study duration is 23 months while the&#xD;
      subject participation duration is 12 months. Subjects assigned to the 3 dose regimen will&#xD;
      receive ANDV DNA vaccine on Days 1, 29 and 169, and placebo on Day 57. Subjects assigned to&#xD;
      the 4 dose regimen will receive ANDV DNA on Days 1, 29, 57 and 169. Two doses (2 or 4 mg) of&#xD;
      ANDV DNA vaccine will be evaluated. The primary objective of this study is to assess the&#xD;
      safety and reactogenicity of the ANDV DNA vaccine by dosage cohort and treatment arm when&#xD;
      administered using the PharmaJet Stratis(R) Needle-Free Injection system in normal, healthy&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48&#xD;
      males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet&#xD;
      all eligibility criteria. This trial is designed to assess the safety, reactogenicity and&#xD;
      immunogenicity of an Andes Virus (ANDV) DNA vaccine for the prevention of Hantavirus&#xD;
      Pulmonary Syndrome (HPS). ANDV DNA vaccine or placebo will be administered using the&#xD;
      PharmaJet Stratis(R) Needle-Free Injection System. The study duration is 23 months while the&#xD;
      subject participation duration is 12 months. Subjects assigned to the 3 dose regimen will&#xD;
      receive ANDV DNA vaccine on Days 1, 29 and 169, and placebo on Day 57. Subjects assigned to&#xD;
      the 4 dose regimen will receive ANDV DNA on Days 1, 29, 57 and 169. Two doses (2 or 4 mg) of&#xD;
      ANDV DNA vaccine will be evaluated. The primary objective of this study is to assess the&#xD;
      safety and reactogenicity of the ANDV DNA vaccine by dosage cohort and treatment arm when&#xD;
      administered using the PharmaJet Stratis(R) Needle-Free Injection system in normal, healthy&#xD;
      adults. The secondary objective of this study is to assess the immunogenicity of the ANDV DNA&#xD;
      vaccine by dosage cohort and treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Actual">September 23, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Clinical Safety Laboratory Adverse Events</measure>
    <time_frame>Day 8, Day 36, Day 64, Day 176</time_frame>
    <description>Laboratory parameters include alanine aminotransferase (ALT), total bilirubin, creatinine, blood urea nitrogen (BUN), hemoglobin, absolute neutrophil count (ANC), sodium, potassium, white blood cells (WBC), and platelet count.&#xD;
Laboratory results were considered adverse events using the following thresholds: ALT 50 IU/L or greater; total bilirubin 1.30 mg/dL or greater; creatinine 0.81 mg/dL or greater (female) or 1.11 mg/dL or greater (male); BUN 24 mg/dL or greater; hemoglobin 11.6 g/dL or lower (female) or 13.2 g/dL or lower (male); ANC &lt;1.8 K/mcL; sodium 135 mmol/L or lower (decrease) or 146 mmol/L or greater (increase); potassium 3.0 mmol/L or lower (decrease) or 5.2 mmol/L or greater (increase); WBC 4.4 K/mcL or lower (decrease) or 13.1 K/mcL or greater (increase 18 to &lt;21 years) and 11.1 K/mcL or greater (increase 21 years or older); or platelets 134 K/mcL or below (decrease) or 467 K/mcL or greater (increase).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAEs) From Day 1 Through Day 337</measure>
    <time_frame>Day 1 through Day 337</time_frame>
    <description>An adverse event was considered serious if it resulted in any of the following outcomes: death, a life-threatening adverse event (its occurrence places the participant at immediate risk of death), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Adverse events can be considered serious when they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Vaccine-Related Serious Adverse Events (SAEs) From Day 1 Through Day 337</measure>
    <time_frame>Day 1 through Day 337</time_frame>
    <description>An adverse event is considered serious if it results in any of the following outcomes: death, a life-threatening adverse event (its occurrence places the participant at immediate risk of death), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Adverse events can be considered serious when they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.&#xD;
An adverse event was considered related to the study product if there was a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197</measure>
    <time_frame>Day 1 through Day 197</time_frame>
    <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of first study vaccination through 28 days after the last study vaccination or after Day 169 if the fourth vaccination wasn't received.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Vaccine-Related Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197</measure>
    <time_frame>Day 1 through Day 197</time_frame>
    <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of first study vaccination through 28 days after the last study vaccination or after Day 169 if the fourth vaccination wasn't received.&#xD;
An adverse event was considered related to the study product if there was a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local Adverse Events From Day 1 Through Day 8</measure>
    <time_frame>Day 1 through Day 8</time_frame>
    <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the first vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local Adverse Events From Day 29 Through Day 36</measure>
    <time_frame>Day 29 through Day 36</time_frame>
    <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the second vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local Adverse Events From Day 57 Through Day 64</measure>
    <time_frame>Day 57 through Day 64</time_frame>
    <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the third vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local Adverse Events From Day 169 Through Day 176</measure>
    <time_frame>Day 169 through Day 176</time_frame>
    <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement, induration, induration measurement, skin discoloration, ecchymosis, and ecchymosis measurement. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the fourth vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Systemic Adverse Events From Day 1 Through Day 8</measure>
    <time_frame>Day 1 through Day 8</time_frame>
    <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the first vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Systemic Adverse Events From Day 29 Through Day 36</measure>
    <time_frame>Day 29 through Day 36</time_frame>
    <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the second vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Systemic Adverse Events From Day 57 Through Day 64</measure>
    <time_frame>Day 57 through Day 64</time_frame>
    <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the third vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Systemic Adverse Events From Day 169 Through Day 176</measure>
    <time_frame>Day 169 through Day 176</time_frame>
    <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the fourth vaccination.&#xD;
Systemic AEs were considered mild severity if they were noticeable but did not interfere with daily activity; events (other than headache) were considered moderate severity if they interfered with daily activity; events (other than headache) were considered severe severity if they caused significant interference and prevented daily activity. Headache events were considered moderate severity if they required any use of pain reliever or interfered with daily activity; headache events were severe if they prevented daily activity or required use of a prescription medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Neutralizing Antibodies to ANDV Measured by Plaque Reduction Neutralization Titers</measure>
    <time_frame>Day 1, Day 57, Day 85, Day 197</time_frame>
    <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. The geometric mean titer was calculated for each study arm from the results available at Day 1 prior to the first study vaccination, 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).&#xD;
Results lower than the limit of detection (&lt;20) were reported and analyzed as 14.1 (which is 20/ sqrt(2)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Neutralizing Antibodies to ANDV Measured by Pseudovirion Neutralization Titers</measure>
    <time_frame>Day 1, Day 57, Day 85, Day 197</time_frame>
    <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. The geometric mean titer was calculated for each study arm from the results available at Day 1 prior to the first study vaccination, 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).&#xD;
Results lower than the limit of detection (&lt;20) were reported and analyzed as 14.1 (which is 20/ sqrt(2)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ANDV Antibody Titers Greater Than or Equal to 20 as Measured by Plaque Reduction Neutralization Titers</measure>
    <time_frame>Day 57, Day 85, Day 197</time_frame>
    <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. The number of participants with a titer greater than or equal to 20 was recorded for each study arm from the results available at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ANDV Antibody Titers Greater Than or Equal to 20 as Measured by Pseudovirion Neutralization Titers</measure>
    <time_frame>Day 57, Day 85, Day 197</time_frame>
    <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. The number of participants with a titer greater than or equal to 20 was recorded for each study arm from the results available at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), 28 days following the fourth study vaccination (Day 197).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ANDV Antibody Seroconversion as Measured by Plaque Reduction Neutralization Titers</measure>
    <time_frame>Day 57, Day 85, Day 197</time_frame>
    <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. A participant was considered to have seroconverted if their titer measured at least 40 if the baseline titer was less than 20, or if there was at least a 4-fold rise in titers from baseline if the baseline titer was greater than or equal to 20. The number of participants seroconverting was recorded for each study arm from the results at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ANDV Antibody Seroconversion at Day 57 as Measured by Pseudovirion Neutralization Titers</measure>
    <time_frame>Day 57, Day 85, Day 197</time_frame>
    <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. A participant was considered to have seroconverted if their titer measured at least 40 if the baseline titer was less than 20, or if there was at least a 4-fold rise in titers from baseline if the baseline titer was greater than or equal to 20. The number of participants seroconverting was recorded for each study arm from the results at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hantavirus Pulmonary Infection</condition>
  <condition>Immunisation</condition>
  <arm_group>
    <arm_group_label>Arm 1 (2 mg ANDV - 3-dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.&#xD;
11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (2 mg ANDV - 4-dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.&#xD;
11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (4 mg ANDV - 3-dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.&#xD;
11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (4 mg ANDV - 4-dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.&#xD;
11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Andes virus DNA vaccine</intervention_name>
    <description>A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
    <arm_group_label>Arm 1 (2 mg ANDV - 3-dose regimen)</arm_group_label>
    <arm_group_label>Arm 2 (2 mg ANDV - 4-dose regimen)</arm_group_label>
    <arm_group_label>Arm 3 (4 mg ANDV - 3-dose regimen)</arm_group_label>
    <arm_group_label>Arm 4 (4 mg ANDV - 4-dose regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System</description>
    <arm_group_label>Arm 1 (2 mg ANDV - 3-dose regimen)</arm_group_label>
    <arm_group_label>Arm 2 (2 mg ANDV - 4-dose regimen)</arm_group_label>
    <arm_group_label>Arm 3 (4 mg ANDV - 3-dose regimen)</arm_group_label>
    <arm_group_label>Arm 4 (4 mg ANDV - 4-dose regimen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent before initiation of any study procedures.&#xD;
&#xD;
          2. Are able to understand and comply with planned study procedures and be available for&#xD;
             all study visits/phone calls.&#xD;
&#xD;
          3. Males or non-pregnant females ages 18-49, inclusive.&#xD;
&#xD;
          4. Are in good health*. *As determined by medical history and physical examination to&#xD;
             evaluate acute or currently ongoing chronic medical diagnoses or conditions, defined&#xD;
             as those that have been present for at least 90 days which would affect the assessment&#xD;
             of the safety of subjects or the immunogenicity of study vaccinations. Chronic medical&#xD;
             diagnoses or conditions should be stable for the last 60 days (no hospitalizations, ER&#xD;
             or urgent care for condition and no adverse symptoms that need medical intervention&#xD;
             such as medication change/supplemental oxygen). This includes no change in chronic&#xD;
             prescription medication, dose, or frequency as a result of deterioration of the&#xD;
             chronic medical diagnosis or condition in the 60 days prior to enrollment. Any&#xD;
             prescription change that is due to change of health care provider, insurance company,&#xD;
             etc., or that is done for financial reasons, as long as in the same class of&#xD;
             medication, will not be considered a deviation of this inclusion criterion. Any change&#xD;
             in prescription medication due to improvement of a disease outcome, as determined by&#xD;
             the site principal investigator or appropriate sub-investigator, will not be&#xD;
             considered a deviation of this inclusion criterion. Subjects may be on chronic or as&#xD;
             needed (prn) medications if, in the opinion of the site principal investigator or&#xD;
             appropriate sub-investigator, they pose no additional risk to subject safety or&#xD;
             assessment of reactogenicity and immunogenicity and do not indicate a worsening of&#xD;
             medical diagnosis or condition. Similarly, medication changes subsequent to enrollment&#xD;
             and study vaccination are acceptable provided there was no deterioration in the&#xD;
             subject's chronic medical condition that necessitated a medication change, and there&#xD;
             is no additional risk to the subject or interference with the evaluation of responses&#xD;
             to study vaccination. Note: Topical, nasal, and inhaled medications (apart from&#xD;
             steroids as outlined in the Subject Exclusion Criteria), herbals, vitamins, and&#xD;
             supplements are permitted.&#xD;
&#xD;
          5. Oral temperature is less than 100.0 degrees Fahrenheit (37.8 degrees Celsius).&#xD;
&#xD;
          6. Pulse is 47 to 105 beats per minute (bpm), inclusive.&#xD;
&#xD;
          7. Systolic blood pressure (BP) is 85 to 150 mm Hg, inclusive.&#xD;
&#xD;
          8. Diastolic blood pressure (BP) is 55 to 95 mm Hg, inclusive.&#xD;
&#xD;
          9. Have acceptable screening laboratories* within 28 days prior to enrollment. *Screening&#xD;
             laboratory values that are outside acceptable range but are thought to be due to an&#xD;
             acute condition or due to laboratory error may be repeated once.&#xD;
&#xD;
         10. Urine protein screen is negative or trace.&#xD;
&#xD;
         11. Drug screen for opiates is negative.&#xD;
&#xD;
         12. HgbA1C &lt; 6.3% at screening.&#xD;
&#xD;
         13. HIV - 1/2 antibody negative.&#xD;
&#xD;
         14. HCV antibody negative.&#xD;
&#xD;
         15. HBsAg negative.&#xD;
&#xD;
         16. Women of childbearing potential*, must be using an effective method of contraception**&#xD;
             from 30 days prior to the first study vaccination until 90 days after the last study&#xD;
             vaccination.&#xD;
&#xD;
             *Women of childbearing potential are defined as those who have not been sterilized via&#xD;
             tubal ligation, bilateral oophorectomy, hysterectomy, or successful Essure(R)&#xD;
             placement (permanent, non-surgical, non-hormonal sterilization) with history of&#xD;
             documented radiological confirmation test at least 90 days after the procedure (or&#xD;
             with use of another birth control method if history of confirmation test not&#xD;
             confirmed), AND are still menstruating or &lt; 1 year since the last menses if&#xD;
             perimenoapausal.&#xD;
&#xD;
             **For this study, we define an effective contraceptive method as one that results in a&#xD;
             failure rate of less than 1% per year when it is used consistently and correctly. This&#xD;
             includes, but is not limited to, non-male sexual relationships, abstinence from sexual&#xD;
             intercourse with a male partner, monogamous relationship with a vasectomized partner,&#xD;
             male condoms with the use of applied spermicide, intrauterine devices, NuvaRing(R),&#xD;
             and licensed hormonal methods such as implants, injectables or oral contraceptives&#xD;
             (&quot;the pill&quot;).&#xD;
&#xD;
         17. Women of childbearing potential* must have a negative serum pregnancy test at&#xD;
             screening and a negative urine pregnancy test within 24 hours prior to each study&#xD;
             vaccination.&#xD;
&#xD;
             *See definition of women of childbearing potential above.&#xD;
&#xD;
         18. Sexually active male participants whose partner is a woman of childbearing potential*&#xD;
             and has not had a vasectomy** must agree not to father a child until 90 days after the&#xD;
             last vaccination***.&#xD;
&#xD;
               -  See definition of women of childbearing potential above. **Performed &gt; 1 year&#xD;
                  prior to screening&#xD;
&#xD;
                    -  Must agree to use a barrier method of birth control e.g., either condom with&#xD;
                       spermicidal foam/gel/film/cream or partner reports usage of occlusive cap&#xD;
                       (diaphragm or cervical/vault caps) with spermicidal&#xD;
                       foam/gel/film/cream/suppository.&#xD;
&#xD;
         19. Women agree to not donate eggs (ova, oocytes) and male subject agrees not to donate&#xD;
             sperm from the start of screening onwards until at least 90 days after the last&#xD;
             vaccination.&#xD;
&#xD;
         20. Agree not to participate in another clinical trial during the study period.&#xD;
&#xD;
         21. Agree not to donate blood to a blood bank for 3 months after receiving the last study&#xD;
             vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant, planning to become pregnant or lactating*. *Includes&#xD;
             breastfeeding or planning to breastfeed at any given time from the receipt of study&#xD;
             vaccination through the 12-month trial period.&#xD;
&#xD;
          2. Known allergy or history of anaphylaxis, severe local or other serious adverse&#xD;
             reactions to vaccines or vaccine products*, or history of severe allergic reactions.&#xD;
&#xD;
             *This includes a known allergy to an aminoglycoside (e.g., gentamicin, tobramycin,&#xD;
             neomycin, streptomycin).&#xD;
&#xD;
          3. Received an experimental agent* within 3 months prior to study vaccination, or expects&#xD;
             to receive an experimental agent** during the 12-month trial-reporting period.&#xD;
&#xD;
             *Including vaccine, drug, biologic, device, blood product, or medication.&#xD;
&#xD;
             **Other than from participation in this study.&#xD;
&#xD;
          4. Received any licensed live vaccine within 28 days prior to or after each study&#xD;
             vaccination.&#xD;
&#xD;
          5. Received a licensed inactivated vaccine within 14 days prior to or after each study&#xD;
             vaccination*.&#xD;
&#xD;
             *Allowable exception for inactivated seasonal influenza vaccine received more than 7&#xD;
             days prior to or after a study vaccination.&#xD;
&#xD;
          6. Individuals in whom the ability to observe possible local reactions at the eligible&#xD;
             injection sites (deltoid region) is, unacceptably obscured due to a physical condition&#xD;
             or permanent body art.&#xD;
&#xD;
          7. Have an acute illness*, as determined by the site PI or appropriate sub-investigator,&#xD;
             within 72 hours prior to study vaccination.&#xD;
&#xD;
             *An acute illness which is nearly resolved with only minor residual symptoms remaining&#xD;
             is allowable if, in the opinion of the site PI or appropriate sub-investigator, the&#xD;
             residual symptoms will not interfere with the ability to assess safety parameters as&#xD;
             required by the protocol. Subjects may re-screen after an acute illness is resolved&#xD;
&#xD;
          8. Any confirmed or suspected immunosuppressive or immunodeficient condition* or use of&#xD;
             anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study&#xD;
             vaccination.&#xD;
&#xD;
             *Including HIV infection&#xD;
&#xD;
          9. Administration of chronic (defined as more than 14 days) immunosuppressants or other&#xD;
             immune modifying drugs within 6 months of receipt of study vaccine*.&#xD;
&#xD;
             *For corticosteroids, this means prednisone, or equivalent, greater than or equal to&#xD;
             0.5 mg/kg/day. Intranasal and topical steroids ARE allowed; daily inhaled steroids for&#xD;
             treatment of asthma NOT allowed.&#xD;
&#xD;
         10. History of receipt of a Hantavirus vaccine, including vaccines for Hantaan virus,&#xD;
             Puumala virus, or combination of both.&#xD;
&#xD;
         11. Exposed to ANDV* or plans to travel to an endemic area** from enrollment through 6&#xD;
             months post last vaccination.&#xD;
&#xD;
             *Residence in an ANDV endemic area in the last 3 years or &gt; 2 consecutive weeks of&#xD;
             travel to an ANDV endemic area** in the last 3 years.&#xD;
&#xD;
             **ANDV endemic areas include Chile, Brazil and Argentina.&#xD;
&#xD;
         12. Any chronic or active neurologic disorder, including seizures and epilepsy, excluding&#xD;
             febrile seizures as a child.&#xD;
&#xD;
         13. History of receiving immunoglobulin or other blood product within the 3 months before&#xD;
             enrollment in this study.&#xD;
&#xD;
         14. Current or past history of alcohol or drug abuse in the last 5 years.&#xD;
&#xD;
         15. Subjects with autoimmune disorders, chronic inflammatory disorders or neurological&#xD;
             disorders with a potential autoimmune correlation.&#xD;
&#xD;
         16. Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other&#xD;
             psychiatric diagnosis that may interfere with subject compliance or safety&#xD;
             evaluations.&#xD;
&#xD;
         17. Have been hospitalized for psychiatric illness, history of suicide attempt, or&#xD;
             confinement for danger to self or others within 10 years prior to study vaccination.&#xD;
&#xD;
         18. Have received any antiviral within 3 days of study vaccination.&#xD;
&#xD;
         19. A diagnosis of Type I or II diabetes.&#xD;
&#xD;
         20. Current employee or staff paid entirely or partially by the contract for this trial,&#xD;
             or staff who are supervised by the PI or Sub-Investigators.&#xD;
&#xD;
         21. Any condition that would, in the opinion of the Site Investigator or appropriate&#xD;
             sub-investigator, is a contraindication to study participation*.&#xD;
&#xD;
               -  Including acute or chronic (persisting for at least 90 days) clinically&#xD;
                  significant medical disease or condition, that would place the subject at an&#xD;
                  unacceptable risk of injury, render the subject unable to meet the requirements&#xD;
                  of the protocol, or may interfere with the evaluation of responses or the&#xD;
                  subject's successful completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 6, 2021</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <results_first_submitted>September 9, 2021</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2021</results_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Andes Virus DNA</keyword>
  <keyword>ANDV DNA</keyword>
  <keyword>Hantavirus</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>PharmaJet Stratis</keyword>
  <keyword>Pulmonary Syndrome</keyword>
  <keyword>Safety</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hantavirus Pulmonary Syndrome</mesh_term>
    <mesh_term>Hantavirus Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03682107/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03682107/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03682107/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study population includes 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health, have not previously received the Hantavirus vaccine, have not been exposed to ANDV, and meet all other eligibility criteria. Participants were enrolled between 19FEB2019 and 04NOV2019 and received study vaccinations between 19FEB2019 and 08APR2020.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2 mg ANDV, 3 Dose Regimen</title>
          <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="P2">
          <title>2 mg ANDV, 4 Dose Regimen</title>
          <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="P3">
          <title>4 mg ANDV, 3 Dose Regimen</title>
          <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="P4">
          <title>4 mg ANDV, 4 Dose Regimen</title>
          <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.&#xD;
Placebo: Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 mg ANDV, 3 Dose Regimen</title>
          <description>2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="B2">
          <title>2 mg ANDV, 4 Dose Regimen</title>
          <description>2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="B3">
          <title>4 mg ANDV, 3 Dose Regimen</title>
          <description>4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="B4">
          <title>4 mg ANDV, 4 Dose Regimen</title>
          <description>4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.&#xD;
Andes virus DNA vaccine: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) or 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.&#xD;
Placebo: Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="6.8"/>
                    <measurement group_id="B2" value="33.8" spread="8.1"/>
                    <measurement group_id="B3" value="34.9" spread="8.9"/>
                    <measurement group_id="B4" value="35.9" spread="10.4"/>
                    <measurement group_id="B5" value="30.6" spread="8.8"/>
                    <measurement group_id="B6" value="34.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Clinical Safety Laboratory Adverse Events</title>
        <description>Laboratory parameters include alanine aminotransferase (ALT), total bilirubin, creatinine, blood urea nitrogen (BUN), hemoglobin, absolute neutrophil count (ANC), sodium, potassium, white blood cells (WBC), and platelet count.&#xD;
Laboratory results were considered adverse events using the following thresholds: ALT 50 IU/L or greater; total bilirubin 1.30 mg/dL or greater; creatinine 0.81 mg/dL or greater (female) or 1.11 mg/dL or greater (male); BUN 24 mg/dL or greater; hemoglobin 11.6 g/dL or lower (female) or 13.2 g/dL or lower (male); ANC &lt;1.8 K/mcL; sodium 135 mmol/L or lower (decrease) or 146 mmol/L or greater (increase); potassium 3.0 mmol/L or lower (decrease) or 5.2 mmol/L or greater (increase); WBC 4.4 K/mcL or lower (decrease) or 13.1 K/mcL or greater (increase 18 to &lt;21 years) and 11.1 K/mcL or greater (increase 21 years or older); or platelets 134 K/mcL or below (decrease) or 467 K/mcL or greater (increase).</description>
        <time_frame>Day 8, Day 36, Day 64, Day 176</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Clinical Safety Laboratory Adverse Events</title>
          <description>Laboratory parameters include alanine aminotransferase (ALT), total bilirubin, creatinine, blood urea nitrogen (BUN), hemoglobin, absolute neutrophil count (ANC), sodium, potassium, white blood cells (WBC), and platelet count.&#xD;
Laboratory results were considered adverse events using the following thresholds: ALT 50 IU/L or greater; total bilirubin 1.30 mg/dL or greater; creatinine 0.81 mg/dL or greater (female) or 1.11 mg/dL or greater (male); BUN 24 mg/dL or greater; hemoglobin 11.6 g/dL or lower (female) or 13.2 g/dL or lower (male); ANC &lt;1.8 K/mcL; sodium 135 mmol/L or lower (decrease) or 146 mmol/L or greater (increase); potassium 3.0 mmol/L or lower (decrease) or 5.2 mmol/L or greater (increase); WBC 4.4 K/mcL or lower (decrease) or 13.1 K/mcL or greater (increase 18 to &lt;21 years) and 11.1 K/mcL or greater (increase 21 years or older); or platelets 134 K/mcL or below (decrease) or 467 K/mcL or greater (increase).</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium increase : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium increase : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC decrease : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC decrease : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC decrease : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC decrease : Day 176</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC increase : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC increase : Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets increased : Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets increased : Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAEs) From Day 1 Through Day 337</title>
        <description>An adverse event was considered serious if it resulted in any of the following outcomes: death, a life-threatening adverse event (its occurrence places the participant at immediate risk of death), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Adverse events can be considered serious when they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</description>
        <time_frame>Day 1 through Day 337</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Serious Adverse Events (SAEs) From Day 1 Through Day 337</title>
          <description>An adverse event was considered serious if it resulted in any of the following outcomes: death, a life-threatening adverse event (its occurrence places the participant at immediate risk of death), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Adverse events can be considered serious when they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Vaccine-Related Serious Adverse Events (SAEs) From Day 1 Through Day 337</title>
        <description>An adverse event is considered serious if it results in any of the following outcomes: death, a life-threatening adverse event (its occurrence places the participant at immediate risk of death), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Adverse events can be considered serious when they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.&#xD;
An adverse event was considered related to the study product if there was a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.</description>
        <time_frame>Day 1 through Day 337</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Vaccine-Related Serious Adverse Events (SAEs) From Day 1 Through Day 337</title>
          <description>An adverse event is considered serious if it results in any of the following outcomes: death, a life-threatening adverse event (its occurrence places the participant at immediate risk of death), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Adverse events can be considered serious when they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.&#xD;
An adverse event was considered related to the study product if there was a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197</title>
        <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of first study vaccination through 28 days after the last study vaccination or after Day 169 if the fourth vaccination wasn't received.</description>
        <time_frame>Day 1 through Day 197</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197</title>
          <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of first study vaccination through 28 days after the last study vaccination or after Day 169 if the fourth vaccination wasn't received.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No unsolicited AEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At least one unsolicited AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Vaccine-Related Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197</title>
        <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of first study vaccination through 28 days after the last study vaccination or after Day 169 if the fourth vaccination wasn't received.&#xD;
An adverse event was considered related to the study product if there was a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.</description>
        <time_frame>Day 1 through Day 197</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Vaccine-Related Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197</title>
          <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of first study vaccination through 28 days after the last study vaccination or after Day 169 if the fourth vaccination wasn't received.&#xD;
An adverse event was considered related to the study product if there was a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At least one related unsolicited AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local Adverse Events From Day 1 Through Day 8</title>
        <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the first vaccination.</description>
        <time_frame>Day 1 through Day 8</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local Adverse Events From Day 1 Through Day 8</title>
          <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the first vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local Adverse Events From Day 29 Through Day 36</title>
        <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the second vaccination.</description>
        <time_frame>Day 29 through Day 36</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local Adverse Events From Day 29 Through Day 36</title>
          <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the second vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local Adverse Events From Day 57 Through Day 64</title>
        <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the third vaccination.</description>
        <time_frame>Day 57 through Day 64</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local Adverse Events From Day 57 Through Day 64</title>
          <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement (measuring &gt;0mm), induration, induration measurement (measuring &gt;0mm), skin discoloration, ecchymosis, and ecchymosis measurement (measuring &gt;0mm). Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the third vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (Measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis (Measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local Adverse Events From Day 169 Through Day 176</title>
        <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement, induration, induration measurement, skin discoloration, ecchymosis, and ecchymosis measurement. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the fourth vaccination.</description>
        <time_frame>Day 169 through Day 176</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local Adverse Events From Day 169 Through Day 176</title>
          <description>Local adverse events solicited on a memory aid provided to participants included pain, tenderness, erythema, erythema measurement, induration, induration measurement, skin discoloration, ecchymosis, and ecchymosis measurement. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the fourth vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (Measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis (Measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 1 Through Day 8</title>
        <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the first vaccination.</description>
        <time_frame>Day 1 through Day 8</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 1 Through Day 8</title>
          <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the first vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 29 Through Day 36</title>
        <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the second vaccination.</description>
        <time_frame>Day 29 through Day 36</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 29 Through Day 36</title>
          <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the second vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 57 Through Day 64</title>
        <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the third vaccination.</description>
        <time_frame>Day 57 through Day 64</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 57 Through Day 64</title>
          <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the third vaccination.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 169 Through Day 176</title>
        <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the fourth vaccination.&#xD;
Systemic AEs were considered mild severity if they were noticeable but did not interfere with daily activity; events (other than headache) were considered moderate severity if they interfered with daily activity; events (other than headache) were considered severe severity if they caused significant interference and prevented daily activity. Headache events were considered moderate severity if they required any use of pain reliever or interfered with daily activity; headache events were severe if they prevented daily activity or required use of a prescription medication.</description>
        <time_frame>Day 169 through Day 176</time_frame>
        <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Systemic Adverse Events From Day 169 Through Day 176</title>
          <description>Systemic adverse events solicited on a memory aid provided to participants included feverishness, malaise, fatigue, myalgia, headache, nausea, dizziness, and fever. Participants were considered to have experienced the AE if they reported an event of mild or greater severity on any of the 7 days following the fourth vaccination.&#xD;
Systemic AEs were considered mild severity if they were noticeable but did not interfere with daily activity; events (other than headache) were considered moderate severity if they interfered with daily activity; events (other than headache) were considered severe severity if they caused significant interference and prevented daily activity. Headache events were considered moderate severity if they required any use of pain reliever or interfered with daily activity; headache events were severe if they prevented daily activity or required use of a prescription medication.</description>
          <population>The Safety Analysis population includes all participants who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies to ANDV Measured by Plaque Reduction Neutralization Titers</title>
        <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. The geometric mean titer was calculated for each study arm from the results available at Day 1 prior to the first study vaccination, 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).&#xD;
Results lower than the limit of detection (&lt;20) were reported and analyzed as 14.1 (which is 20/ sqrt(2)).</description>
        <time_frame>Day 1, Day 57, Day 85, Day 197</time_frame>
        <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies to ANDV Measured by Plaque Reduction Neutralization Titers</title>
          <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. The geometric mean titer was calculated for each study arm from the results available at Day 1 prior to the first study vaccination, 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).&#xD;
Results lower than the limit of detection (&lt;20) were reported and analyzed as 14.1 (which is 20/ sqrt(2)).</description>
          <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed for any arm at Day 1 due to a lack of variation in the data.</measurement>
                    <measurement group_id="O2" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed for any arm at Day 1 due to a lack of variation in the data.</measurement>
                    <measurement group_id="O3" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed for any arm at Day 1 due to a lack of variation in the data.</measurement>
                    <measurement group_id="O4" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed for any arm at Day 1 due to a lack of variation in the data.</measurement>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed for any arm at Day 1 due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.4" upper_limit="27.7"/>
                    <measurement group_id="O2" value="24.6" lower_limit="13.1" upper_limit="46.3"/>
                    <measurement group_id="O3" value="37.3" lower_limit="13.9" upper_limit="99.7"/>
                    <measurement group_id="O4" value="24.6" lower_limit="10.5" upper_limit="57.2"/>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                    <measurement group_id="O2" value="45.9" lower_limit="14.5" upper_limit="145.3"/>
                    <measurement group_id="O3" value="28.2" lower_limit="13.1" upper_limit="60.8"/>
                    <measurement group_id="O4" value="34.8" lower_limit="13.5" upper_limit="89.4"/>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="11.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="68.5" lower_limit="14.5" upper_limit="324.2"/>
                    <measurement group_id="O3" value="50.4" lower_limit="17.6" upper_limit="143.9"/>
                    <measurement group_id="O4" value="217.7" lower_limit="71.7" upper_limit="660.9"/>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies to ANDV Measured by Pseudovirion Neutralization Titers</title>
        <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. The geometric mean titer was calculated for each study arm from the results available at Day 1 prior to the first study vaccination, 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).&#xD;
Results lower than the limit of detection (&lt;20) were reported and analyzed as 14.1 (which is 20/ sqrt(2)).</description>
        <time_frame>Day 1, Day 57, Day 85, Day 197</time_frame>
        <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies to ANDV Measured by Pseudovirion Neutralization Titers</title>
          <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. The geometric mean titer was calculated for each study arm from the results available at Day 1 prior to the first study vaccination, 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).&#xD;
Results lower than the limit of detection (&lt;20) were reported and analyzed as 14.1 (which is 20/ sqrt(2)).</description>
          <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                    <measurement group_id="O2" value="14.1" lower_limit="12.9" upper_limit="17.6"/>
                    <measurement group_id="O3" value="14.1" lower_limit="11.0" upper_limit="26.8"/>
                    <measurement group_id="O4" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="10.1" upper_limit="48"/>
                    <measurement group_id="O2" value="35.6" lower_limit="15.8" upper_limit="80.4"/>
                    <measurement group_id="O3" value="200.1" lower_limit="30.5" upper_limit="1312.4"/>
                    <measurement group_id="O4" value="68.8" lower_limit="17.2" upper_limit="276.1"/>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">NA Explanation: A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="10.8" upper_limit="28.1"/>
                    <measurement group_id="O2" value="67.1" lower_limit="19.3" upper_limit="233.6"/>
                    <measurement group_id="O3" value="119.4" lower_limit="27.2" upper_limit="524.2"/>
                    <measurement group_id="O4" value="186.1" lower_limit="38.2" upper_limit="905.9"/>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">NA Explanation: A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="16" upper_limit="791.8"/>
                    <measurement group_id="O2" value="230.5" lower_limit="70.8" upper_limit="750.8"/>
                    <measurement group_id="O3" value="234.8" lower_limit="50" upper_limit="1103.3"/>
                    <measurement group_id="O4" value="808.2" lower_limit="168.2" upper_limit="3882.4"/>
                    <measurement group_id="O5" value="14.1" lower_limit="NA" upper_limit="NA">NA Explanation: A confidence interval was not able to be computed due to a lack of variation in the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ANDV Antibody Titers Greater Than or Equal to 20 as Measured by Plaque Reduction Neutralization Titers</title>
        <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. The number of participants with a titer greater than or equal to 20 was recorded for each study arm from the results available at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
        <time_frame>Day 57, Day 85, Day 197</time_frame>
        <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ANDV Antibody Titers Greater Than or Equal to 20 as Measured by Plaque Reduction Neutralization Titers</title>
          <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. The number of participants with a titer greater than or equal to 20 was recorded for each study arm from the results available at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
          <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ANDV Antibody Titers Greater Than or Equal to 20 as Measured by Pseudovirion Neutralization Titers</title>
        <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. The number of participants with a titer greater than or equal to 20 was recorded for each study arm from the results available at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), 28 days following the fourth study vaccination (Day 197).</description>
        <time_frame>Day 57, Day 85, Day 197</time_frame>
        <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ANDV Antibody Titers Greater Than or Equal to 20 as Measured by Pseudovirion Neutralization Titers</title>
          <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. The number of participants with a titer greater than or equal to 20 was recorded for each study arm from the results available at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), 28 days following the fourth study vaccination (Day 197).</description>
          <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ANDV Antibody Seroconversion as Measured by Plaque Reduction Neutralization Titers</title>
        <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. A participant was considered to have seroconverted if their titer measured at least 40 if the baseline titer was less than 20, or if there was at least a 4-fold rise in titers from baseline if the baseline titer was greater than or equal to 20. The number of participants seroconverting was recorded for each study arm from the results at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
        <time_frame>Day 57, Day 85, Day 197</time_frame>
        <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ANDV Antibody Seroconversion as Measured by Plaque Reduction Neutralization Titers</title>
          <description>Venous blood was collected to perform a 50% plaque reduction neutralization test (PRNT) which was conducted with Andes Virus as the antigen. A participant was considered to have seroconverted if their titer measured at least 40 if the baseline titer was less than 20, or if there was at least a 4-fold rise in titers from baseline if the baseline titer was greater than or equal to 20. The number of participants seroconverting was recorded for each study arm from the results at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
          <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O2" value="30" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O3" value="40" lower_limit="12.2" upper_limit="73.8"/>
                    <measurement group_id="O4" value="20" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="40" lower_limit="12.2" upper_limit="73.8"/>
                    <measurement group_id="O3" value="30" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O4" value="40" lower_limit="12.2" upper_limit="73.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                    <measurement group_id="O2" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O3" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                    <measurement group_id="O4" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ANDV Antibody Seroconversion at Day 57 as Measured by Pseudovirion Neutralization Titers</title>
        <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. A participant was considered to have seroconverted if their titer measured at least 40 if the baseline titer was less than 20, or if there was at least a 4-fold rise in titers from baseline if the baseline titer was greater than or equal to 20. The number of participants seroconverting was recorded for each study arm from the results at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
        <time_frame>Day 57, Day 85, Day 197</time_frame>
        <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg ANDV, 3 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O2">
            <title>2 mg ANDV, 4 Dose Regimen</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O3">
            <title>4 mg ANDV, 3 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O4">
            <title>4 mg ANDV, 4 Dose Regimen</title>
            <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ANDV Antibody Seroconversion at Day 57 as Measured by Pseudovirion Neutralization Titers</title>
          <description>Venous blood was collected to perform a 50% pseudovirion neutralization assay (PsVNA) which was conducted with Andes Virus as the antigen. A participant was considered to have seroconverted if their titer measured at least 40 if the baseline titer was less than 20, or if there was at least a 4-fold rise in titers from baseline if the baseline titer was greater than or equal to 20. The number of participants seroconverting was recorded for each study arm from the results at 28 days following the second study vaccination (and immediately prior to the third study vaccination; Day 57), 28 days following the third study vaccination (Day 85), and 28 days following the fourth study vaccination (Day 197).</description>
          <population>All participants in the intent-to-treat (ITT) population with valid results available at the given time point were included. Participants were included in the ITT population if they received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination for immunogenicity testing for which valid results (results are not missing and the laboratory did not deem the sample or results unfit for analysis) were reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.8" upper_limit="60"/>
                    <measurement group_id="O2" value="30" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O3" value="60" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O4" value="50" lower_limit="18.7" upper_limit="81.3"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0.3" upper_limit="44.5"/>
                    <measurement group_id="O2" value="40" lower_limit="12.2" upper_limit="73.8"/>
                    <measurement group_id="O3" value="60" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O4" value="70" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                    <measurement group_id="O2" value="77.8" lower_limit="40" upper_limit="97.2"/>
                    <measurement group_id="O3" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O4" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs were collected through 28 days following the final vaccination, up to Day 197; SAEs were collected through Day 337.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2 mg ANDV, 3 Dose Regimen</title>
          <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
        </group>
        <group group_id="E2">
          <title>2 mg ANDV, 4 Dose Regimen</title>
          <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
        </group>
        <group group_id="E3">
          <title>4 mg ANDV, 3 Dose Regimen</title>
          <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
        </group>
        <group group_id="E4">
          <title>4 mg ANDV, 4 Dose Regimen</title>
          <description>4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 in a double-blinded manner. Sentinel subjects received all doses in an open label manner.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>2 mg (2 injections of 0.5 mL (1 mg/0.5 mL each)) or 4 mg (2 injections of 0.5 mL (2 mg/0.5 mL each)) of placebo intramuscularly into the left and right deltoid on Days 1, 29, 57, and 169 in a double-blinded manner.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <description>Acute Rhabdomyolysis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="17" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="15" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" events="11" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaccination site discolouration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="37" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="32" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" events="22" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" events="34" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="30" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E4" events="26" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="36" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="25" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E4" events="27" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="11" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="25" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diziness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" events="14" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Paulsen</name_or_title>
      <organization>Cincinnati Children's Hospital</organization>
      <phone>513-636-4578</phone>
      <email>Grant.Paulsen@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

